EMERYVILLE, Calif., May 03, 2018 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it successfully collaborated with its fragrance partner, Firmenich, to support the development and commercialization of Z11. This sustainable and cost-effective version of Firmenich’s iconic Z11 molecule was developed using Amyris’s disruptive proprietary technology to develop a reliable and sustainable supply of an intermediate, using a fermentation-based production process, for which Firmenich has then applied its state of the art, proprietary green chemistry.
“We are pleased with our ability to support Firmenich’s product innovation as they continue to be a leader in developing game-changing ingredients for their customers,” said John Melo, President & CEO of Amyris. “Amyris has collaborated with Firmenich since 2010, successfully growing a palette of bio-based fragrance ingredients and intermediates as Firmenich continues their legacy of providing the finest ingredients well into the future, with the added benefit of being derived from a sustainable resource.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Amyris and the Amyris logo are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners.
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
[email protected]
[email protected]


SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 



